此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Vibrato Aspiration System - Simple, Intuitive Approach to Clot Removal in Acute Pulmonary Embolism - a Safety & Feasibility Study

2026年8月23日 更新者:Vicora, Inc.
The study is a prospective, single-arm, multicenter study to evaluate the safety and effectiveness of the Vibrato™ Aspiration System for aspiration mechanical thrombectomy in the treatment of acute PE. This is the First in Man clinical study.

研究概览

地位

招聘中

详细说明

The study objective is to evaluate the safety and effectiveness of the Vibrato™ Aspiration System Aspiration System (hereafter referred to as Vibrato™ Aspiration System) for aspiration mechanical thrombectomy in the treatment of acute PE.

The Vibrato™ Aspiration System is a vibration-assisted aspiration thrombectomy device including attributes designed to improve trackability, maintain a low-profile configuration, and operate without capital equipment. In addition, the Vibrato™ Aspiration System features a novel vibrating distal tip designed to enhance thrombus removal during aspiration while minimizing vascular injury. The vibrating mechanism may reduce procedure times, improve clot removal efficiency, and decrease the need for adjunctive interventions.

研究类型

介入性

注册 (估计的)

10

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Greater Poland Voivodeship
      • Poznan、Greater Poland Voivodeship、波兰、61-848
        • 尚未招聘
        • Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu Uniwersytecki Szpital Kliniczny
        • 首席研究员:
          • Aleksander Araszkiewicz, Professor, MD, PhD
    • Lesser Poland Voivodeship
      • Krakow、Lesser Poland Voivodeship、波兰、31-202
        • 招聘中
        • Krakowski Szpital Specjalistyczny im. św. Jana Pawła II
        • 首席研究员:
          • Grzegorz Kopeć, Professor, MD, PhD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

Subjects must meet all following general inclusion criteria:

  1. Age ≥ 18 and ≤ 75 years.
  2. Clinical signs, symptoms, and presentation consistent with acute PE;
  3. PE symptom duration ≤ 14 days;
  4. CTA evidence (site determined) of proximal PE (filling defect in at least one main or interlobar pulmonary artery)
  5. RV/LV ratio of ≥ 0.9 on CTA as assessed by investigator (site determined).
  6. Systolic blood pressure ≥ 90 mmHg;
  7. Stable heart rate < 130 BPM prior to procedure;
  8. Patient is deemed medically eligible for interventional procedure(s), per institutional guidelines and clinical judgment
  9. Informed Consent Form signed
  10. Subject is willing and able to comply with all Clinical Investigation Plan required follow-up visit

Exclusion Criteria:

Subjects must not meet any of the following general exclusion criteria:

  1. Thrombolytic use within 30 days of baseline CT angiogram
  2. Pulmonary hypertension with peak pulmonary artery pressure > 70 mmHg by right heart catheterization (site determined)
  3. Vasopressor requirement after fluids to keep pressure ≥ 90 mmHg;
  4. FiO2 requirement > 40% or > 6 LPM to keep oxygen saturation > 90%;
  5. Hematocrit < 28%;
  6. Platelets < 100,000/ML;
  7. Serum creatinine > 1.8 mg/dL;
  8. International normalized ratio (INR) > 3;
  9. Major trauma injury severity score (ISS) > 15 within the past 14 days
  10. Presence of intracardiac lead in the right ventricle or right atrium placed within 6 months, Pacemaker or Implantable Cardioverter Defibrillators;
  11. Cardiovascular or pulmonary surgery within last 7 days;
  12. Actively progressing cancer requiring chemotherapy
  13. Known bleeding diathesis or coagulation disorder;
  14. Left bundle branch block;
  15. History of severe or chronic pulmonary arterial hypertension;
  16. History of chronic left heart disease with left ventricular ejection fraction ≤ 30%;
  17. History of uncompensated heart failure;
  18. History of underlying lung disease that is oxygen dependent;
  19. History of chest irradiation;
  20. History of heparin-induced thrombocytopenia (HIT);
  21. Patients who are under intubation
  22. Any contraindication to systemic or therapeutic doses of heparin or anticoagulants;
  23. Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated;
  24. Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the Subject is not appropriate for mechanical thrombectomy intervention;
  25. Life expectancy of < 90 days, as determined by Investigator;
  26. Female who is pregnant or nursing;
  27. Current participation in another investigational drug or device treatment study
  28. History of Hemorrhagic or Ischemic Stroke, including Transient Ischemic Attack, within last 90 days
  29. Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:设备可行性
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Single arm study
Vibrato™ Aspiration System for aspiration mechanical thrombectomy in the treatment of acute pulmonary embolism.
Mechanical Thrombectomy for the treatment of Acute Pulmonary Embolism

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Safety Endpoint: Major Adverse Events
大体时间:48 hours

Major Adverse Events, a composite of:

  • Device-related death within 48 hours
  • Major bleeding within 48 hours
  • Device-related AEs within 48 hours, including:
  • Clinical deterioration
  • Pulmonary vascular injury
  • Cardiac injury
48 hours
Efficacy Endpoint: Reduction in RV/LV Ratio
大体时间:48 hours
Reduction in RV/LV ratio from baseline to 48 hours or discharge by CT angiography
48 hours

次要结果测量

结果测量
措施说明
大体时间
Safety Endpoint: Device-Related Death
大体时间:48 hours
Device-related death within 48 hours
48 hours
Safety Endpoint: Major Bleeding
大体时间:48 Hours
Major bleeding within 48 hours
48 Hours
Safety Endpoint: Device-Related Clinical Deterioration
大体时间:48 Hours
Device-related clinical deterioration within 48 hours
48 Hours
Safety Endpoint: Device-Related Pulmonary Vascular Injury
大体时间:48 Hours
Device-related pulmonary vascular injury within 48 hours
48 Hours
Safety Endpoint: Cardiac Injury
大体时间:48 Hours
Cardiac injury within 48 hours
48 Hours
Safety Endpoint: Any-Cause Mortality
大体时间:30 Days
Any-cause mortality within 30 days
30 Days
Safety Endpoint: Device-Related Serious Adverse Event
大体时间:30 Days
Device-related Serious Adverse Events (SAEs) within 30 days
30 Days
Safety Endpoint: Symptomatic Recurrence of Pulmonary Embolism
大体时间:30 Days
Symptomatic recurrence of Pulmonary Embolism (PE) within 30 days
30 Days
Efficacy Endpoint: Modified Miller Index Score
大体时间:48 Hours
Change in modified Miller Index Score (MMIS) between baseline and 48 hours post-procedure as assessed by CTA
48 Hours
Efficacy Endpoint: Change in Mean Pulmonary Artery Pressure
大体时间:Procedure
Change in mean pulmonary artery pressure measured invasively in the central pulmonary arteries before vs. after the endovascular procedure [measured in mmHg]
Procedure
Efficacy Endpoint: Procedural Change in Cardiac Index
大体时间:Procedure
Procedural change in cardiac index [measured in L/min/m^2]
Procedure
Efficacy Endpoint: Length of ICU Stay, Associated with Index Procedure
大体时间:30 Days
Length of stay in the ICU associated with the index procedure [measured in days]
30 Days
Efficacy Endpoint: Length of Total Hospital Stay
大体时间:30 Days
Length of total hospital stay [measured in days]
30 Days
Efficacy Endpoint: Post-Index Procedure Hospital Length of Stay
大体时间:30 Days
Post-index-procedure hospital length of stay [measured in days]
30 Days
Efficacy Endpoint: Procedural Reduction in Pulmonary Artery Mean Pressure
大体时间:Procedure
Procedural reduction in pulmonary artery mean pressure [measured in mmHg]
Procedure
Efficacy Endpoint: Procedural Reduction in Pulmonary Artery Systolic Pressure
大体时间:Procedure
Procedural reduction in pulmonary artery systolic pressure [measured in mmHg]
Procedure
Efficacy Endpoint: Reduction in Total Pulmonary Vascular Resistance
大体时间:Procedure
Procedural reduction in total pulmonary vascular resistance [measured in mmHg ⋅ min/L]
Procedure
Efficacy Endpoint: Change from Baseline in Dyspnea Severity by mMRC Score
大体时间:48 Hours
Change from baseline in Dyspnea severity by mMRC score at the 48-hour visit
48 Hours
Efficacy Endpoint: Change from Baseline in Dyspnea Severity by mMRC Score
大体时间:30 Days
Change from baseline in Dyspnea severity by mMRC score [Time Frame: at the 30 days visit]
30 Days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

合作者

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年8月21日

初级完成 (估计的)

2026年10月1日

研究完成 (估计的)

2026年12月1日

研究注册日期

首次提交

2026年6月18日

首先提交符合 QC 标准的

2026年7月1日

首次发布 (实际的)

2026年7月6日

研究记录更新

最后更新发布 (实际的)

2026年8月25日

上次提交的符合 QC 标准的更新

2026年8月23日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

其他研究编号

  • 26-VIC-0001

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅